Revolutionizing Eye Care for Rare Diseases
We're focused on delivering healing to those who need it most
At Eliksa, we're at the forefront of biotechnological advancements to address unmet needs in eye care. Our exclusive products leverage the regenerative potential of specialized biological components, fostering healing for ocular conditions. Each product undergoes meticulous processing in our state-of-the-art cGMP regenerative medicine facility, ensuring a consistent acellular solution while preserving the vital biological components.
Eyes on Tomorrow
Paving the Path for EB Ocular Care
We're on a transformative journey in regenerative medicine, with a particular focus on the ocular manifestations of Epidermolisis Bullosa (EB), an ultra-rare genetic disorder that primarily affects children. ELK-003, our groundbreaking investigational ophthalmic drug, delivered in the form of eye drops, represents a pioneering step towards addressing this longstanding, unmet need.
We are proud to partner with leading innovators, clinical researchers and investors to bring our proprietary regenerative technologies to patients.
MILITIA HILL VENTURES
BEN FRANKLIN TECHNOLOGY PARTNERS